

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Mapping the Existing Body of Knowledge on New and Repurposed TB Vaccine Implementation: A Scoping Review

Joeri S. Buis¹, Degu Jerene^{1*}, Agnes Gebhard¹, Roel Bakker¹, Arman Majidulla², Andrew D. Kerkhoff³, Rupali Limaye², Puck T. Pelzer¹

¹KNCV Tuberculosis Foundation, The Hague, The Netherlands

²Johns Hopkins University, Bloomberg School of Public Health, Baltimore, USA

³Division of HIV, Infectious Diseases and Global Medicine Zuckerberg San Francisco General Hospital and Trauma Center, and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA

*Corresponding author
Degu.dare@kncvtbc.org

Acknowledgement:

SMART4TB is made possible by the generous support of the American people through the United States Agency for International Development (USAID) and is implemented under cooperative agreement number 7200AA20CA00005. The consortium is managed by prime recipient, the Johns Hopkins University.

Disclaimer:

This study/report/publication is made possible by the support of the American people through the United States Agency for International Development (USAID). The contents are the sole responsibility of (authors) and do not necessarily reflect the views of USAID, the United States Government, or consortium collaborators or members.

Abstract

There is global consensus on the urgent need for a safe and effective TB vaccine for adults and adolescents to improve global TB control, and encouragingly, several promising candidates have advanced to late-stage trials. Significant gaps remain in understanding the critical factors that will facilitate the successful implementation of new and repurposed TB vaccines in low- and middle-income countries (LMICs), once available. By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these adults and adolescent vaccines. This review explores four key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities. Results indicate that current research primarily consists of epidemiological and costing/cost-effectiveness/economic studies in India, China, and South Africa, mainly modelling with M72/AS01, BCG revaccination, and generic vaccines. Varying endpoints, vaccine efficacies, and vaccination coverages were used. Globally, new, and repurposed TB vaccines are estimated to save millions of lives. Economically, these vaccines also demonstrate promise with expected cost-effectiveness in most countries. Projected outcomes were dependent on vaccine characteristics, target population, implementation strategy, timing of roll out, TB burden/country context, and vaccination coverage. Potential barriers for vaccine acceptability included TB-related stigma, need for a second dose, and cost, while low pricing, community and civil society engagement and heightened public TB awareness were potential enablers in China, India, and South Africa. Potential implementation strategies considered spanned from mass campaigns to integration within existing vaccine programs and the primary target group studied was the general population, and adults and adolescents. In conclusion, future research must have broader geographical representations to better understand what is needed to inform tailored vaccine programs to accommodate diverse country contexts and population groups to achieve optimal implementation and impact. Furthermore, this review underscores the scarcity of research on acceptability of new and repurposed TB vaccines and their delivery among potential beneficiaries, the most promising implementation strategies, and the health system capabilities necessary for implementation. The absence of this knowledge in these areas emphasizes the crucial need for future research to ensure effective TB vaccine implementation in high burden settings worldwide.

73 Introduction

74 Tuberculosis (TB) remains a persistent global health challenge, imposing a significant burden on communities
75 worldwide, despite substantial health efforts, including the availability of effective treatment, and widespread
76 use of the Bacillus Calmette–Guerin (BCG) vaccine. In 2022 alone, 10.6 million people fell ill with TB, with
77 approximately 1.3 million deaths¹. Of all reported TB patients, 99% were in low- and middle-income countries
78 (LMICs¹). India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic
79 of Congo, account for approximately two-thirds of all patients worldwide. The development of new and
80 repurposed tuberculosis (TB) vaccines is a promising approach with the potential to transform TB prevention,
81 aiding (LMICs) in achieving the World Health Organization (WHO)'s End TB targets¹. The WHO has identified
82 new and repurposed vaccines as a cornerstone of the WHO End TB Strategy, with the ultimate goal to build a
83 world without TB¹. Effective implementation will be pivotal for maximizing public health impact once new
84 and/or repurposed vaccines are available.

85
86 Currently, the BCG vaccine is the only licensed vaccine against TB. First employed in 1921, the vaccine is one of
87 the most widely used vaccines globally, with 80% of all countries recommending BCG vaccination for
88 neonates², and a coverage of >80% on average. BCG vaccination primarily prevents severe forms of TB in
89 young children and multiple limitations have been identified: varying effectiveness, contraindication in people
90 who are living with HIV/AIDS (PLHIV), and the lack of protection against reactivation of TB. Additionally, there
91 is little evidence that it prevents the development of TB in adults and adolescents³. These are important
92 limitations as adults and adolescents account for about 90% of TB incidence and TB is the leading cause of
93 death from a single infectious agent in PLHIV^{1,4}.

94
95 To fill the critical research and development gap in TB vaccines, there has been an increase in clinical trials
96 evaluating the effectiveness and safety of TB vaccine candidates that target adults and adolescents.
97 Approximately 17 TB vaccine candidates are in the clinical development pipeline, of which six have progressed
98 to phase 3 development and are intended for use in adults and adolescents^{4,5}. These include MIP, VMP1002,
99 GamTBvac, MTBVAC, BCG (re)vaccination, and M72/AS01E. Of these, promising phase 2b results were
100 published for the M72/AS01E vaccine, revealing a vaccine efficacy of 49.7% (90% confidence interval [CI]=12.1
101 to 71.2 and 95% CI=2.1 to 74.2) against development of TB disease over a three year follow-up period⁵. For
102 BCG revaccination in adolescents between the ages of 12-17 years, vaccine efficacy in preventing TB infection
103 was estimated at 45.4% (95% CI, 6.4 to 68.1)⁶. While clinical trials are instrumental in evaluating the safety and
104 efficacy of TB vaccine candidates, evidence on vaccine implementation beyond the clinical trial setting is
105 critical to achieving public health impact. There is an urgent need to understand how to effectively implement
106 and scale-up vaccination programs to achieve optimal public health impact, following the approval of new and
107 repurposed TB vaccines.

108
109 In the last few years, evidence has accumulated regarding the potential impact of new and repurposed TB
110 vaccines. Modelling studies have shown that a new TB vaccine with an efficacy of at least 50% for preventing
111 the development of TB disease, a faster and broader impact could be achieved targeting adults and
112 adolescents rather than infants and children⁷. However, Harris et al. argue that some approaches used in the
113 modelling – such as campaigns specifically targeting uninfected people – may not be feasible due to the high
114 cost and inaccuracies of available tuberculin skin tests to exclude TB infection⁷.

¹ LMICs includes low-, lower-middle, and upper-middle income countries depending on the Gross National Income ([Low- and Middle-income Countries - List | Wellcome](#))

Two recent documents, the Global Roadmap for Research and Development for TB Vaccines and the Evidence Considerations for Vaccine Policy (ECVP), identify key actions and considerations to prepare for the effective implementation of a new and repurposed TB vaccine, once approved^{8,9}. Crucial TB vaccine implementation components to realizing successful TB vaccination programs for adults and adolescents in LMICs include understanding the TB burden, the public health and economic impact of TB vaccination in target populations, developing and implementing strategic plans for TB vaccination, strengthening healthcare capacity and infrastructure, enhancing public awareness, and increasing acceptance among the public^{8,9}.

A comprehensive review and synthesis of the existing literature on best practices regarding acceptability and feasibility of implementing new or repurposed TB vaccines for adults and adolescents has not yet been undertaken, nor has an overview of projected epidemiological impact and costing, cost-effectiveness and economic impact.² This work would offer critical insights to understanding what will be needed to prepare for and contribute to the effective launch and scalable delivery of a licensed TB vaccine upon availability, including the identification of knowledge gaps.

Therefore, the objective of this scoping review is to assess and synthesize existing research and evidence on TB vaccine implementation in adults and adolescents in LMICs, regarding projected epidemiological impact, economic impact, acceptability, and feasibility, and identify priority areas for future research to prepare for deployment of new and repurposed TB vaccines. The specific questions included:

What is the existing body of knowledge on the:

1. epidemiological impact of new and repurposed TB vaccines targeting adults and/or adolescents as estimated by modelling studies?
2. costing, cost-effectiveness, and/or economic impact of new and repurposed TB vaccines targeting adults and/or adolescents as estimated by modelling studies?
3. acceptability of new and repurposed TB vaccines targeting adults and/or adolescents?
4. implementation feasibility of vaccination programs using new and repurposed TB vaccines, targeting adults and/or adolescents?
 - a. the potential implementation strategies for new and repurposed TB vaccines?
 - b. the existing body of knowledge on health system readiness for the implementation and scale up of a new and repurposed TB vaccine?

Methods

Study design overview

We employed a narrative synthesis approach¹⁰, sourcing literature from PubMed, Medrxiv, PLOS journals, and expert suggestions. Articles were selected using a systematic method, and data extraction and analysis were carried out iteratively using the Roadmap⁸ and ECVP⁹.

Search Methods

The narrative synthesis approach involved three systematic search components: (1) database search, (2) search on internet sites, and (3) identification of relevant articles by the team. The search strings for the database queries combined the following concepts: TB, TB vaccination, and vaccine preparedness. A

² A separate review is assessing lessons learnt from vaccine introductions, other than new and repurposed TB vaccines.

158 combination of Medical Subject Headings (MeSH) terms and separate keywords relating to the research
159 questions were included to create a broad and inclusive search strategy. All concepts included variations of
160 the keywords. Filtering removed non-human, infant/children, clinical, and immunological studies, limiting to
161 English articles published between 2013-2023. Using the search strings, article retrieval was carried out on
162 30th April 2023. The detailed search strings are provided in Annex A.

- 163 1. Databases: Searches were conducted using PubMed and Medrxiv.
- 164 2. Internet sites: PLOS journals were identified as having relevant literature related to this topic, however
165 not all PLOS journals were indexed in PubMed or Medrxiv at the time of conducting the search.
166 Therefore, a quick literature search was conducted within the PLOS journal.
- 167 3. Identification of additional literature: to accommodate the identification of articles currently not
168 covered within the above search components, additional literature identified by the internal team of
169 experts on TB vaccine readiness were also included.

171 Inclusion and exclusion criteria

172 Scientific literature (including preprints) related to the implementation of a new and repurposed TB vaccines
173 for adults and adolescent was included (Table 1). We focused on studies conducted in or concentrating on
174 LMICs and we focused on articles published between 2013 and 2023. Expanding the timeframe was not
175 anticipated to yield additional relevant articles, given that the development of TB vaccine candidates has been
176 a more recent occurrence. Studies focusing on vaccine candidates moving to/are in phase 3 trials were
177 included as were generic vaccines that align with the WHO Preferred Product Characteristics (PPC)⁸. Literature
178 covering other types of vaccines, (clinical/non-human) trials, and immunological studies were excluded.
179 Studies on BCG vaccines (other than explicitly related to a revaccination strategy) were also excluded as were
180 studies focused on the efficacy/effectiveness, and safety of new and repurposed TB vaccines. The primary
181 focus of our review was on collecting primary data regarding the implementation of new and repurposed TB
182 vaccines. Consequently, we chose not to include a grey literature search, as our expectation was that this type
183 of literature might not predominantly contain primary data.

184
185 *Table 1. Inclusion and exclusion criteria for selection of literature.*

Inclusion criteria	Exclusion criteria
Type of study: Studies (including preprints) on the preparedness and implementation of new and repurposed TB vaccines	Non-human trials and immunology studies
Country category: Low- and middle-income countries	TB vaccines trials on efficacy/ effectiveness, and safety
Age group: Adults and/or adolescents, with the specific age as defined in the study	Children, infants, neonates
Language: English only	BCG for neonates
Conducted between 2013-2023	Books, guidelines, frameworks, roadmaps, presentations

187 Selection of articles

188 The literature assessment occurred in a sequential process. Initially, articles from PubMed and Medrxiv were
189 imported into Zotero, where their abstracts and titles were evaluated for relevance. Simultaneously, PLOS
190 journal articles were examined directly on its website, and those meeting the relevancy criteria were
191 individually added to Zotero, unless already detected through the other searches. Subsequently, a
192 comprehensive full-text screening was conducted to in- or exclude articles, while removing duplicates. In
193 instances where articles reported secondary results, the initial paper was added. JSB undertook the initial
194 selection, screening, and assessment. PTP checked a random sample of articles to ensure consistency in the
195 inclusion process. After title and abstract screening, JSB checked articles for their relevance through a full-text
196 assessment. JSB consulted PTP to discuss articles for potential inclusion in cases of uncertainty. After full-text
197 inclusion, the data were subtracted and collected in an extraction sheet using Excel 2023. A thorough

assessment (snowballing) of the references was performed on both the articles cited within the identified reviews and the final selected articles to ascertain any potentially relevant literature that was not captured within the initial search strategies. Similarly, any articles identified through the review of references and reviews followed the same structured inclusion process, as did any additional articles identified by the team.

Data extraction and analysis

The AIGHD/EDCTP Roadmap and WHO's Evidence Considerations for Vaccine Policy^{8,9} provided key implementation factors for ensuring public health impact in shaping our analytical framework. Four pivotal implementation research components were evaluated: (1) Epidemiological impact (e.g. cases and deaths averted by vaccine), (2) Economic impact – on health systems, societies, macroeconomic-, value for money (e.g. cost per death or DALY averted, budget impact and impact on equity and social protection, including costing and cost-effectiveness), (3) Acceptability by potential target population (i.e. the likely acceptability, including barriers and enablers, of the vaccine in the target populations and other key stakeholder groups), and (4) Implementation feasibility by potential target population (i.e. practicality of vaccine implementation, considering the logistics, delivery, and program related considerations). We adapted the conceptual framework from Atun¹¹ based on these key components (Figure 1).

We listed the number of studies conducted within each component in an Excel sheet by country and evaluated each study based on the four components. Results were reported for countries separately, outlining the vaccine characteristics, anticipated vaccination coverage, and time spans of the projected TB vaccine roll out. Implementation feasibility was further assessed through the lens of WHO's health systems building blocks¹²: health service delivery, health workforce, health information systems, accessibility, health financing, and leadership and governance.




Figure 1. Conceptual framework of factors influencing implementation of TB vaccination among adults and adolescents^{9,11}.

Results

Articles output

We identified 1,807 articles of which 682 were from PubMed and 1,125 from Medrxiv (Figure 2). Following title and abstract screening of these initial articles and after removal of duplicates, 81 articles were included for full-text screening. The search strategy for PLOS journals resulted in the identification of two additional articles, which were included for full-text screening. Of the 83 articles for full-text inclusion that were reviewed, 66 articles did not meet the inclusion criteria of which seven articles referenced other articles with primary data. Five articles were identified through snowballing and one additional article was added by the team, resulting in 23 total articles for inclusion. Of the 23 articles, 18 were peer-reviewed, and 5 were scientific preprints.




Figure 2. Flow diagram of article selection.

238 Study characteristics

239 A total of 23 articles were included in the review. Table 2 provides an overview of the number of included
240 studies per country, vaccine readiness focus, vaccine candidate or profile, and vaccine endpoints. Most of the
241 research was conducted in/ or focused on India (9 studies), followed by high burden LMICs in general (7
242 studies), and articles specific by country: South Africa (7 studies), China (6 studies), Indonesia (1 study), and
243 Cambodia (1 study). Among the key research topics on TB vaccine implementation, epidemiological impact
244 was the most frequently assessed topic (16 studies), followed by costing, cost-effectiveness, and/or economic
245 impact (11 studies). One article addressed acceptability within the context of implementation feasibility, with
246 a specific focus on exploring implementation strategies and health system readiness while five articles
247 assessed implementation strategies. Various vaccine candidates and profiles were covered in the literature,
248 including M72 /AS01e (8 studies), BCG revaccination (5 studies), and generic vaccines (15 studies). Endpoints
249 for the generic vaccines, most frequently encompassed prevention of disease (PoD) (14 studies), while
250 prevention of infection (PoI) (6 studies) was less common; no study modelled a prevention of recurrence (PoR)
251 endpoint (see table 3).

253 Epidemiological and Costing, Cost-effectiveness, and/or Economic Modelling Studies

254 A total of 21 studies estimated the epidemiological and/or costing, cost-effectiveness, and/or economic
255 benefits of new and repurposed TB vaccines as shown in table 4 & 5. The studies were conducted across
256 multiple LMICs, with India (8 studies) leading, followed by South Africa, China, Indonesia, and Cambodia.
257 Epidemiological impact projection took precedence, as 16 studies estimated the effects of vaccines on health
258 outcomes. Additionally, 11 studies explored the costing, cost-effectiveness, and/or economic implications of
259 vaccine implementation, emphasizing the comprehensive evaluation of benefits. The studies examined various
260 vaccine candidates and profiles, with generic vaccines being the most common (14 studies), followed by
261 M72/AS01E (PoD) (7 studies) and BCG revaccination (PoI) (3 studies). The primary endpoints of the generic
262 vaccine profiles modelled with were PoD (13 studies) and PoI (5 studies) (see table 6 & 7).

264 Epidemiological impact

265 Epidemiological impact studies were mostly conducted in India (6) or in LMICs/various high burden countries
266 in general (4), China (4), and South Africa (4). Vaccine candidates and profiles modelled with were generic
267 vaccines (11), M72/AS01E (5), and BCG revaccination (3). Of the studies modelling with a generic vaccine, 9
268 studies used a PoD endpoint, 5 used PoI, and none used PoR. Most studies (11) focused on the general
269 adult/adolescent population, 1 on adolescents only, 1 on the general population, 1 on miners, 1 on people
270 with diabetes mellitus (DM), and one within a geographic hotspot with a high TB incidence (see table 6).

271
272 Overall, the epidemiological impact of a new and repurposed PoD TB vaccine was found to be substantial
273 compared to a no TB vaccine scenario (beyond BCG vaccination in neonates), with the highest health gains
274 projected within the groups/countries with the highest TB burden (see Table)¹³⁻¹⁷. Based on studies focusing
275 on a selection of LMICs, the delivery strategy with the highest projected epidemiological impact consisted of
276 routine vaccination with an instantly rolled out mass vaccination campaign, and concurrent with other public
277 health interventions such as improved diagnostics, treatment, and reduced delay in health-seeking¹³⁻¹⁷. A new
278 or repurposed PoD TB vaccine with an efficacy of 60% was found to help reach the End TB targets if a minimal
279 coverage of 72% could be achieved in South Asia, Central Asia Republics and Europe (CAR/EU) and 40% in Sub-
280 Saharan countries. This difference for Sub-Saharan countries is due to the projected impact of TPT uptake in
281 PLHIV¹³.

283 Country-specific studies revealed differences in impact as vaccine characteristics, target population and
284 implementation strategy, timing of roll out, TB burden, and vaccination coverage rates vary. In China, a PoD
285 vaccine targeting older people, protective in both mycobacterium tuberculosis (Mtb.) infected and recovered
286 populations, could deliver the highest impact¹⁸. In South Africa, Jayawardena et al.¹⁹ projected the largest
287 epidemiological impact with a strategy implementing a sequence of two mass vaccination campaigns and a
288 second South African study found that a PoD vaccine could be most impactful if effective in both uninfected
289 and infected people, and safe for use among PLHIV²⁰. Moreover, Shrestha et al.²¹ found a greater impact of a
290 miner-targeted vaccine strategy compared to a community-targeted strategy in associated labour sending
291 communities in South Africa. This was due to the higher concentration of adult men in the miner target
292 population. In India, Silva et al. found that a vaccination program's effectiveness targeting high incidence
293 geographic areas depends on interaction of populations between geographic areas. Vaccination of people in a
294 well-connected area with high TB incidence could reduce incidence 1.6-fold or more²². Another study showed
295 in Indonesia and India that vaccinating either all ages or 18-49 year olds could bring substantial health and
296 economic gains ,and both health and economic gains would be more substantial with vaccinating all age
297 groups²³.

Table 4. Study outcomes from studies modelling health impacts.

Author, year	Country	TB vaccine	Endpoint (VE ³)	Coverage	Timespan	Target population	Implementation	Projected impact
Knight, 2014 ¹⁷	91 LMICs	Generic vaccine	PoD (60%)	<ul style="list-style-type: none"> Routine vaccination: Coverage based on school attendance level. Mass vaccination: 75% 	2024-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 10-year-olds Mass program: 11+year olds 	17 (95% range: 11–24) million TB cases could be averted
Clark, 2023 ¹⁵	105 LMICs	Generic vaccine	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2028-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9years olds Mass program: 10+ year olds. 	<p>Routine vaccination only: 8.8 million TB cases could be averted. 1.1 million TB deaths could be averted.</p> <p>Routine + one time campaign 44 million TB cases could be averted. 5 million TB deaths could be averted.</p> <p>Quick scale up routine + one time campaign 65.5 million TB cases averted. 7.9 TB deaths averted</p>
Arinaminpathy, 2022 ¹³	24 high burden countries	Generic vaccine	PoD (60%)	<ul style="list-style-type: none"> South Asia: 72% CAR/EU: 72% Sub-Saharan Africa: 40% 	2022-2030	Adults and adolescents	<ul style="list-style-type: none"> Mass vaccination: scaled up linearly 	<p>Mass vaccination + combination other interventions⁴</p> <p>South Asia Annual incidence rate from 325 TB cases per 100k to <75 TB cases per 100k Annual mortality rate from 32 TB deaths per 100k to 7 TB deaths per 100k</p> <p>Sub-Saharan Africa Annual incidence rate from 205 TB cases per 100k to 75 TB cases per 100k Annual mortality rate from 47 TB deaths per 100k to 8 TB deaths per 100k</p> <p>CAR/EU Annual incidence rate from 50 TB cases per 100k to 19 TB cases per 100k</p>

³ Vaccine efficacy

⁴ Improved diagnostics, routine TB services, upstream case-finding, preventive therapy, mass vaccination

								Annual mortality rate from 5 TB deaths per 100k to <2 TB deaths per 100k
Fu, 2021 ¹⁴	30 high RR-TB burden countries	M72/AS01E	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: Coverage based on school attendance level. Mass vaccination: 72–76% 	2020-2035	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 15-year-olds Mass vaccination: 15+ year olds 	<p>Vaccination only 620,000 (95% credible intervals [CrI]: 516,000–867,000) RR-TB cases could be averted</p> <p>Vaccination + improved management of RR-TB 831,000 (95% CrI: 643,000–1,170,000) RR-TB cases could be averted</p>
Harris, 2020 ²⁰	China, India, South Africa	BCG revaccination & M72/AS01E	PoD & Pol (70%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2025-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9-year-olds Mass vaccination: 10+ year olds 	<p>Vaccine with POI + POD</p> <p>China 11.6 million (10.2 to 12.6 million) TB cases could be averted. 0.3 million (0.1 to 0.5 million) TB deaths could be averted.</p> <p>South Africa 4.3 million (2.5 to 7.0 million) TB cases could be averted. 0.9 million (0.5 to 1.6 million) TB deaths could be averted.</p> <p>India 4.3 million (2.5 to 7.0 million) TB cases could be averted. 0.9 million (0.5 to 1.6 million) TB deaths could be averted.</p>
Silva, 2021 ²³	India, Indonesia	M72/AS01E	PoD (49.7%)	<ul style="list-style-type: none"> Mass vaccination: 90% 	2020-2050	Adults and adolescents	<ul style="list-style-type: none"> Mass vaccination: coverage reached in 10 years 	<p>India 2.3 million TB deaths could be averted.</p> <p>Indonesia 695,000 TB deaths could be averted.</p>
Weerasuriya, 2021 ²⁴	China, India	Generic vaccine	PoD & Pol (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2027-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9-year-olds Mass vaccination: 10+ year olds 	<p>Pre-infection and post-infection vaccine</p> <p>India 2.0 (UI: 1.4–4.1) million RR/MDR-TB cases could be averted 0.4 (0.3–0.7) million RR/MDR-TB deaths could be averted</p> <p>China</p>

								<p>2.1 (UI: 1.1–2.7) million RR/MDR-TB cases could be averted 0.1 (0.0–0.2) million RR/MDR-TB deaths could be averted</p> <p>Post-infection vaccine</p> <p>India 1.3 (0.9–2.6) million RR/MDR-TB cases could be averted 0.3 (0.2–0.4) million RR/MDR-TB deaths could be averted</p> <p>China 0.7 (0.5–0.9) million RR/MDR-TB cases could be averted 0.04 (0.02–0.06) million RR/MDR-TB deaths could be averted</p>
Dye, 2013 ²⁵	South Africa	BCG revaccination	Pol (80%)	100%	Not provided	Adolescents	<ul style="list-style-type: none"> Vaccination: 15-year-olds 	17% of cases could be averted
Shrestha, 2017 ²¹	South Africa	Generic vaccine	PoD (60%)	Not provided	20 years	Miners (18–60-year-olds) and (mining) labor sending community	<ul style="list-style-type: none"> Routine vaccination of new and repurposed miners at recruitment Integration with medical examination 	<p>Targeting miners 8,090 (95% range, 3,750–13,300) TB cases could be averted</p> <p>Targeting (mining) labor sending community 5,510 cases (95% range, 2,360–10,000) TB cases could be averted</p>
Jayawardana, 2022 ¹⁹	South Africa	M72/AS01E	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: 40% Mass vaccination: 60% 	2025-2050	Adults and adolescents, PLHIV	<ul style="list-style-type: none"> Routine vaccination: 18–50-year-olds Mass vaccination: 18–50-year-olds 	<p>All 18–50-year-olds Mass + routine vaccination 315,256 TB cases could be averted. 61,718 TB deaths could be averted.</p> <p>2 mass vaccination campaigns 490,008 TB cases could be averted. 96,417 TB deaths could be averted.</p> <p>All PLHIV adults Mass+ routine vaccination 209,524 TB cases could be averted. 42,143 TB deaths could be averted.</p> <p>2x mass vaccination 367,862 TB cases could be averted. 73,191 TB deaths could be averted</p>

Harris, 2019 ¹⁸	China	Generic vaccine	PoD (60%)	70%	2025-2050	Adolescents and elderly	<ul style="list-style-type: none"> • Routine vaccination: 15-year-olds • Mass vaccination: 16–19 years olds • Mass vaccination: 60 64-year-olds 	<p>Pre infection</p> <p>Adolescents 248,000 (214,000–292,000) TB cases could be averted 3,000 (2,000–5,000) TB deaths could be averted</p> <p>Elderly 370,000 (287,000–504,000) TB cases could be averted 9 (5–21) TB deaths could be averted</p> <p>Post infection latency only</p> <p>Adolescents 8,000 (6,000–11,000) TB cases could be averted 90 (50–200) TB deaths could be averted</p> <p>Elderly 658,000 (131,000–1081,000) TB cases could be averted 16,000 (2,000–45,000) TB deaths could be averted</p> <p>Post infection latency or recovered.</p> <p>Adolescents 12,000 (9,000–16,000) TB cases could be averted 140 (70–290) TB deaths could be averted</p> <p>Elderly 1,295,000 (1,037,000–1,469,000) TB cases could be averted 33,000 (16,000–65,000) TB deaths could be averted</p> <p>Pre infection and post infection</p> <p>Adolescents 259,000 (224,000–304,000) TB cases could be averted 3,000 (2,000–5,000) TB deaths could be averted</p> <p>Elderly 1,643,000 (1,403,000–1,893,000) TB cases could be averted 42,000 (22,000–81,000) TB deaths could be averted</p>
----------------------------	-------	-----------------	-----------	-----	-----------	-------------------------	--	---

Liu, 2017 ²⁶	China	Generic vaccine	PoI (75%)	100%	2018-2035	General population	<ul style="list-style-type: none"> Pulse vaccination of all ages (except neonatal which has its own campaign) 	Mixed vaccination The proportion of infectious population reduces to <0.002
Awad. 2020 ²⁷	India	Generic vaccine	PoD & PoI (50%)	50%	2020-2050	People with diabetes mellitus	Not specified	Conservative post-exposure vaccine 1.7 million cases could be averted. Combination of pre- and post-exposure vaccine 7.1 million TB cases could be averted
Shrestha, 2016 ²²	India	Generic vaccine	PoD (60%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination in hotspot⁵: 80% Mass vaccination general population 14-18% 	10 years	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 10-year-olds Mass vaccination of 20+ year olds in hotspot or general population 	Spatially targeted vaccination (STV) program TB incidence reduction of 28% Universal targeted vaccination program TB incidence reduction of 24%
Clark, 2023 ²⁸	India	M72/AS01E, BCG revaccination, generic vaccine	PoD & PoI (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2025-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 15-year-olds Mass vaccination: 16+ year olds 	M72/AS01E 12.7 (95% uncertainty interval: 11.0–14.6) million TB cases could be averted 2.0 (1.8–2.4) million TB deaths could be averted BCG revaccination 9.0 (7.8–10.4) million TB cases could be averted 1.5 (1.3–1.8) million TB deaths could be averted
Renardy, 2019 ²⁹	Cambodia	Generic vaccine	PoD & PoI (100%)	80-99%	2021-2075	Adults and adolescents	<ul style="list-style-type: none"> Mass vaccination of varying age groups 	Yearly, TB cases could go from 300 per 100,000 to <50 per 100,000 depending on age groups.

** LMICs: Low-income countries (LIC), and lower middle-income countries (LMIC). LICs are countries with a GNI per capita of \$1,135 or less and LMICs with a GNI per capita between \$1,136 and \$4,465. GNI per capita may differ per year. ([World Bank Country and Lending Groups – World Bank Data Help Desk](#)).

*** High burden countries: Afghanistan, Bangladesh, Burma, Cambodia, India, Indonesia, Pakistan, Philippines, Vietnam, DR Congo, Ethiopia, Kenya, Malawi, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, Zimbabwe, Kyrgyz Republic, Tajikistan, Ukraine, Uzbekistan

**** High RR-TB high burden countries: India, Pakistan, Indonesia, Philippines, Myanmar, Bangladesh, Ethiopia, Russia Federation, Ukraine, south Africa, Mozambique, DR Congo, Zimbabwe, Nigeria, Thailand, Angola, Kenya, China, Vietnam, DPR Korea, Kazakhstan, Uzbekistan, Somalia, Peru, Kyrgyzstan, Papua New and repurposed Guinea, Tajikistan, Belarus, Republic of Moldova, Azerbaijan.

⁵ Area with a high TB burden

298 Costing, Cost-effectiveness, and/or Economic impact

299 Eleven studies investigated costing, cost-effectiveness, and economic impacts (see table 5 & 7). The
300 distribution of studies included general LMICs (4) and studies in India (5), South Africa (3), China (2), and
301 Indonesia (1). Across the studied countries, the M72/AS01E vaccine candidate was most frequently studied in
302 India (4 studies), whereas generic PoD vaccines were investigated across India (5), South Africa (3), China (2),
303 and Indonesia (1). Costing, cost-effectiveness, and economic measurement outcomes differed across studies,
304 with cost-effectiveness estimated for all except one country (Indonesia). Overall, adults and adolescents from
305 the general population were the most frequently modelled target populations.

306
307 In studies focused on LMICs, adult/adolescent TB vaccine strategies could be economically beneficial
308 compared to situations without new and repurposed TB vaccines. However, this is dependent on the TB
309 burden, prevalence of HIV co-infection, vaccine program approaches, and ultimately the efficacy and duration
310 of protection of the vaccine^{16,17,30,31}. An adult/adolescent TB vaccine was found to be cost-effective in most
311 countries and cost-saving in 58 LMICs³⁰, with higher TB incidence countries gaining the most benefit.
312 Furthermore, an adult/adolescent vaccine program could reduce catastrophic costs by 40%, with the highest
313 gains in the lowest income quintiles¹⁶.

314
315 Country-specific estimates also illustrate that costing, cost-effectiveness, and economic impact is dependent
316 on vaccine characteristics, TB burden, country-specific context and thresholds for cost-effectiveness, coverage,
317 and timing of a program. In India, M72/AS01E is 7-times more cost-effective than BCG revaccination despite
318 cost-effectiveness being evident across all scenarios²⁸. Additionally, Harris et al. found that only a vaccine
319 which includes efficacy in uninfected people was cost-effective. This was due to the epidemic in India and their
320 specific thresholds for cost-effectiveness³². In South Africa, a PoD vaccine could be highly cost-effective and
321 even the least effective PoD vaccine scenario (80% coverage of 10 year olds, post-infection protection)
322 remained below the cost-effectiveness threshold³². The inclusion of HIV-related costs was a relevant
323 contextual factor in South Africa as mortality caused by TB among PLHIV will be prevented by the vaccine. In
324 China, Harris et al. found that a PoD vaccine effective in both TB infected and uninfected people could be most
325 cost-effective based on RR-TB reductions²⁴. Another study by Harris et al. found that in India and South Africa,
326 the costs of vaccinating 18 year olds with 50% coverage was equal to the costs of vaccinating 15 year olds with
327 80% coverage³². Lastly, Silva et al. demonstrated that for India and Indonesia, a delay in implementation from
328 2020 to 2025 and the subsequent loss in economic impact could be recovered by vaccinating all ages instead
329 of only a specific age group (18-49 year olds)²³.

Table 5. Main outcomes from studies modelling costing, cost-effectiveness, and economic impact.

Author, year	Country	TB vaccine	Endpoint (VE ⁶)	Coverage	Time span	Target population	Implementation	Projected impact
Portnoy, 2023 ³⁰	105 LMICs	Generic vaccine	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2028-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9-year-olds Mass vaccination: 10+ year olds 	Incremental net monetary benefit for countries in which vaccination was cost effective. \$372 billion (range: \$283 to 474 billion)
Portnoy, 2022 ³¹	105 LMICs	Generic vaccine	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2028-2080	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9-year-olds Mass vaccination :9+ year olds 	Total absolute GDP gains in LMICs \$1618 billion (range: \$764 to 2988 billion)
Knight, 2014 ¹⁷	96 LMICs	Generic vaccine	PoD (80%)	<ul style="list-style-type: none"> Routine: coverage based on school attendance level Mass vaccination: 75% 	2024-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 10-year-olds Mass vaccination: 11+ year olds 	Cumulated reduction (MDR)-TB treatment costs LIC \$5.3 million LMIC \$35.6 billion UMIC \$133.4 billion
Portnoy, 2022 ¹⁶	105 LMICs	Generic vaccine	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2028-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9 years olds Mass vaccination: 10+ year olds. 	Total averted costs borne by TB-affected households. \$38.9 (\$36.6–41.5) billion could be averted Averted number of households with catastrophic costs 22.9 (21.4–24.5) million households facing catastrophic costs could be averted
Weerasuriya, 2021 ²⁴	China, India	Generic vaccine	PoD & Pol (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2027-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 9-year-olds Mass vaccination: 10+ year olds 	Total vaccination program costs China \$41.5 (39.8–42.6) million India \$38.6 (37.1–39.9) million TB program savings China \$5.2 (3.9–6.8) million India \$19.4 (13.0–27.2) million

⁶ Vaccine efficacy

Silva, 2021 ²³	India, Indonesia	M72/AS01E	PoD (49.7%)	90%	2020-2050	Adults and adolescents	<ul style="list-style-type: none"> Mass vaccination: coverage reached in 10 years 	<p>Vaccine introduced in 2025.</p> <p>India \$2 trillion losses in income could be averted.</p> <p>Indonesia \$680 billion losses in income could be averted</p>
Weerasuriya, 2021 ³³	China, India	M72/AS01E	PoD (50%)	70%	2027-2050	Adults and adolescents	<ul style="list-style-type: none"> Mass vaccination: 10+ year olds Mass vaccination: various age groups 	<p>Country-specific willingness to pay threshold.</p> <p>India \$21 billion is the willingness to pay for a vaccine program. \$5 billion for vaccinating the highest efficiency group (50-59y)</p> <p>China \$15 billion is the willingness to pay for a vaccine program. \$6 billion for vaccinating the highest efficiency group (60-60y)</p>
Harris, 2022 ³²	India, South Africa	M72/AS01E	PoD (50%)	<ul style="list-style-type: none"> Routine vaccination (10years old): 80% Routine vaccination (15years old): 80% Routine vaccination (18 years old): 50% 	2025-2050	Adolescents	<ul style="list-style-type: none"> Routine vaccination: 10-year-olds Routine vaccination: 15-year-olds Routine vaccination: 18-year-olds 	<p>Pre- and post-infection efficacy; 18-year-olds, 50% coverage</p> <p>India \$-135.1 (-324.4, 19.6) cost per DALY averted from societal perspective.</p> <p>South Africa \$290.1 (58.3, 723.1) cost per DALY averted from societal perspective</p>
Clark, 2023 ²⁸	India	M72/AS01E, BCG revaccination, Generic vaccine	PoD & Poi (50%)	<ul style="list-style-type: none"> Routine vaccination: 80% Mass vaccination: 70% 	2025-2050	Adults and adolescents	<ul style="list-style-type: none"> Routine vaccination: 15-year-olds Mass vaccination: 16+ year olds 	<p>Annual incremental program cost</p> <p>BCG revaccination US\$23 million M72/AS01E \$190 million</p> <p>ICER (US\$/DALY averted) from a societal perspective. M72/AS01E \$139 (77–229) per DALY averted</p> <p>BCG revaccination \$17 (cost-saving<71) per DALY averted</p>
Dye, 2013 ²⁵	South Africa	BCG revaccination	Poi (80%)	100%	-	Adolescents	<ul style="list-style-type: none"> Vaccination of 15-year-olds 	<p>\$52 –\$4540 per DALY averted</p>

Jayawardana, 2022 ¹⁹	South Africa	M72/AS0 1E	PoD (50%)	<ul style="list-style-type: none"> • Routine vaccination: 40% • Mass vaccination: 60% 	2025-2050	Adults and adolescents, PLHIV	<ul style="list-style-type: none"> • Routine vaccination: 18–50-year-olds • Mass vaccination: 18–50-year-olds 	<p>Most cost-effective strategy: 2 mass vaccination campaigns 18–50-year-olds \$184 million reduced TB related costs</p> <p>Total incremental cost \$417 (IQR 400–433 million) million</p>
---------------------------------	--------------	------------	-----------	---	-----------	-------------------------------	---	--

** LMICs: Low-income countries (LIC), and lower and upper middle-income countries (LMIC). LICs are countries with a GNI per capita of \$1,135 or less and LMICs with a GNI per capita between \$1,136 and \$4,465. Upper middle-income economies are those with a GNI per capita between \$4,466 and \$13,845. GNI per capita may differ per year ([World Bank Country and Lending Groups – World Bank Data Help Desk](#)).

330 **Acceptability**

331 One study assessed the acceptability of TB vaccine implementation in India, China, and South Africa³⁴. This
 332 article evaluated acceptability among high level vaccine policy and TB experts (Table 8. Factors influencing
 333 acceptability and demand of a new and repurposed TB vaccine). In all three countries, barriers included TB-
 334 related stigma affecting coverage during a mass vaccination campaign as well as affordability. Barriers to
 335 uptake specific to China included vaccine hesitancy and perceived level of protection. In India, experts
 336 perceived negative publicity of side effects as barrier to acceptability by the public and were hesitant about
 337 BCG revaccination resulting from previous trials showing no effects among Indian children. South African
 338 specific barriers included vaccine hesitancy and the need for a second dose of a vaccine candidate. The
 339 facilitators identified across countries included low price per dose, and public awareness of TB disease and the
 340 new and repurposed TB vaccine. Moreover, routine vaccination strategies, engaging communities/civil
 341 societies, and familiarity with the vaccine (in the case of BCG revaccination) were considered facilitators in the
 342 Chinese and South African contexts.

343 *Table 8. Factors influencing acceptability and demand of a new and repurposed TB vaccine³⁴*
 344

	India	China	South Africa
Beliefs and attitudes	-	-	-
Barriers	<ul style="list-style-type: none"> • Stigma • Negative publicity of side effects • High cost • Implementing the BCG revaccination 	<ul style="list-style-type: none"> • Stigma • Vaccine hesitancy • High cost • Low perceived level of protection 	<ul style="list-style-type: none"> • Stigma • Vaccine hesitancy • The need for a second dose • High cost
Enablers /Facilitators	<ul style="list-style-type: none"> • High awareness, especially among elderly • Low price 	<ul style="list-style-type: none"> • Routine vaccination • Vaccination campaign Integrated within national immunization program. • High awareness/health education • Community engagement • Low price • Familiarity with the BCG vaccine if BCG revaccination is implemented 	<ul style="list-style-type: none"> • Routine vaccination • Strong political commitment • Lessons learned from the COVID-19 vaccination program. • Civil society engagement • Low price • Familiarity with the BCG vaccine if BCG revaccination is implemented

345

345 **Implementation feasibility**

346 Five articles contained information on key considerations for implementation feasibility, including
 347 implementation strategies of an adult/adolescent TB vaccine in LMIC, and health system readiness^{19,21,22,34,35}.
 348 shows the number of implementation feasibility studies by country. Three countries were investigated, with
 349 South Africa being the most represented.

351 **Implementation strategies by target population**

352 Five articles contained information related to country-specific implementation strategies, in the context of
 353 China, India, and South Africa (Table 9)^{19,21,22,34,35}. Various strategies for TB vaccine implementation were
 354 identified, which are summarized in table 10. Target populations that were similar across the countries were
 355 adolescents, adults, socially vulnerable groups, PLHIV and other people with immunocompromised systems,
 356 and healthcare workers^{34,35}. The elderly and high risk contacts were target populations evaluated in India and
 357 China³⁴ and in South Africa the mining-community was evaluated as a target population²¹. In the Indian
 358 context, a focus on high-risk populations by targeting high incidence geographic ‘hotspots’ was also
 359 assessed²².

360 *Table 10. Overview of studies assessing implementation strategies*

Author, year	Country	TB vaccine	Endpoint	Time span	Target population	Implementation strategies
Pelzer, 2022 ³⁴	China, India, South Africa	M72/ BCG revaccination	Pol/PoD	2025-2030	<ul style="list-style-type: none"> • Adolescents • Adults • Elderly • Socially vulnerable groups • PLHIV • Immunocompromised • HCW • Other 	<ul style="list-style-type: none"> • Routine vaccinations • Targeted vaccination programs • Mass campaigns • Integration into existing healthcare systems
Hatherill, 2016 ³⁵	South Africa	Generic vaccine & BCG revaccination	Pol/PoD	Not specific	<ul style="list-style-type: none"> • Healthcare workers 	<ul style="list-style-type: none"> • Integration within the occupational health infrastructure
Shresta, 2016 ²²	India	Generic vaccine	PoD	Not specific	<ul style="list-style-type: none"> • Population living in geographic high incidence TB ‘hotspots’ 	<ul style="list-style-type: none"> • Spatially targeted vaccine program
Shresta, 2017 ²¹	South Africa	Generic vaccine	PoD	Not specific; 20 years	<ul style="list-style-type: none"> • Mining population 	<ul style="list-style-type: none"> • Routine vaccination of new and repurposed miners at recruitment • Integration with medical examination
Jayawardana, 2022 ¹⁹	South Africa	M72	PoD	2025-2050	<ul style="list-style-type: none"> • Adults/adolescents and PLHIV adults 	<ul style="list-style-type: none"> • Mass vaccination combined with routine annual vaccination of 18-year-olds, two mass campaigns

362

363 Health system readiness

364 Two articles discussed health system readiness for new and repurposed TB vaccine implementation in India,
 365 China, and South Africa (Table 11. Overview of studies assessing health system readiness)^{34,35}. For all three
 366 countries, there was a described need for an extensive monitoring and surveillance system to track potential
 367 adverse events. In India, it was mentioned that a mass vaccination campaign could be hindered by new and
 368 repurposed cold chain requirements, while routine vaccination could be more easily integrated within the
 369 existing public health system. Additionally, testing for Mtb. infection was considered too expensive and
 370 unfeasible in India. In South Africa, testing for Mtb. infection and the high prevalence of HIV infection -which
 371 may limit which vaccines could be safely used- were also potential challenges. In China, storage capacity was
 372 an additional factor that could delay effective implementation, yet the current procurement and supply chain
 373 could manage the integration of a new and repurposed vaccine program. In South Africa and China,
 374 insufficient staff capacity could hinder any future vaccination campaign.

375 *Table 11. Overview of studies assessing health system readiness.*

Health system readiness		India	China	South Africa ⁷
Health service delivery	Barrier	<ul style="list-style-type: none"> New and repurposed cold chain requirements Testing for Mtb. infection 	<ul style="list-style-type: none"> There may be limited storage capacity. Storage at -80C 	<ul style="list-style-type: none"> Scarcity and price of the adjuvants (for M72/AS01E) Testing for Mtb. infection and high prevalence of HIV infection.
	Facilitator	<ul style="list-style-type: none"> Routine vaccination 	<ul style="list-style-type: none"> Current procurement and supply chain management systems can handle out roll. 	<ul style="list-style-type: none"> Single dosing administered by the lowest level healthcare worker without reliance on a supply chain. Information about the epidemiology, TBI and subnational BCG coverage
Health workforce	Barrier	-	<ul style="list-style-type: none"> Staff workload 	<ul style="list-style-type: none"> Limited number of nurses
	Facilitator	-	-	-
HIS accessibility	Barrier	<ul style="list-style-type: none"> Lack of monitoring and surveillance system for tracking potential adverse events 	<ul style="list-style-type: none"> Lack of monitoring and surveillance system for tracking potential adverse events; 	<ul style="list-style-type: none"> Lack of monitoring and surveillance system for tracking potential adverse events
	Facilitator	-	-	-
Health financing		See table 3 for the projected costing, cost-effectiveness, and economic impacts	See table 7 for the projected costing, cost-effectiveness, and economic impacts	See table 3 for the costing, cost-effectiveness, and economic impacts
Leadership		-	-	-
Governance		-	-	-

377

⁷ These components would also have to be in place in the hospital when targeting healthcare workers.

Discussion

In this scoping review, we found that there is limited body of evidence on implementation potentials of new and repurposed TB vaccines among adults and adolescents. Most studies assessed epidemiological or costing/cost-effectiveness and/or economic impacts of new and/or repurposed TB vaccines followed by implementation feasibility while only one study contained information regarding acceptability among high level stakeholders. The Sub-Saharan African region was underrepresented in all the studies assessed in this review. While our findings clearly highlight the availability of evidence that points toward potential impacts of new and repurposed TB vaccines among adults and adolescents, it also underscores the need for broader geographic and target population representation in the research field.

While the epidemiological studies showed that new and repurposed TB vaccines may avert millions of TB cases and TB deaths¹⁵, the estimated impacts differed per country and were dependent on vaccine characteristics, target population and implementation strategy, the timing of roll out, the local TB burden, and vaccination coverage^{18–23}. Costing, cost-effectiveness, and economic studies showed that in a majority of countries, and remarkably, in 58 LMICs, an adult/adolescent vaccine program could potentially not only be cost-effective but even yield cost-savings outcomes³⁰. Vaccine characteristics, TB burden, cost-effectiveness, coverage, and timing all influence costing, cost-effectiveness, and economic-related outcomes^{15–17,23,24,28,30,32}. Vaccine candidates and profiles modelled with included generic vaccines, M72/AS01E, and BCG revaccination like candidates. Vaccine efficacies ranged from 50%-100%, with coverage rates between 40%-100%. Most studies focused on PoD, some on Pol, and the target population was mainly general adults and adolescents. The study investigating factors influencing acceptability of new and repurposed TB vaccines in India, South Africa, and China showed that countries may differ in their preference for a vaccine candidate and barriers/benefits. In all three countries, common barriers included TB-related stigma affecting coverage during a mass vaccination campaign as well as affordability. Facilitators identified across countries were low price per dose, and public awareness of TB disease and the new and repurposed TB vaccine³⁴. Lastly, studies focusing on implementation feasibility showed that strategies could include mass campaign(s), integrated within existing routine vaccine programs, and targeted campaigns specifically for -for example- miners, elderly, PLHIV, and people with immunocompromising conditions. This will be dependent on country specific context in terms of burden and health system readiness and capabilities^{19,21,22,34,35}.

While this scoping review identified limited information on implementation feasibility, prior research confirms the few findings and underscores the need for more research in this field to ensure effective implementation, once a new and/or repurposed TB vaccine is available. Vaccine hesitancy, lack of availability of monitoring and surveillance systems, affordability and funding/cost of delivery, and storage requirements were also challenges identified in previous studies^{36–38}. Additionally, estimating target population size, slow roll-out of the vaccination campaign, accessibility, and wars/conflicts were additional challenges mentioned in reviews specifically focusing on LMICs^{38,39}. A holistic and timely implementation planning process, expanding access, reducing out-of-pocket costs, one-dose vaccine programs, extensive community involvement, and implementation of programs in schools could circumvent some of these challenges^{36,38,39}. Notably, as assessed in the review by Wang et al., introducing a new vaccine may also have broader positive effects on the general health system⁴⁰. They found that besides reductions in the disease burden, improvements in disease and adverse events surveillance, training, cold chain and logistics capacity and injection safety were documented as beneficial effects. However, they also emphasize that opportunities for strengthening the broader health system were consistently missed during out roll⁴⁰.

422 Research in LMICs other than India, China, and South Africa was lacking, which is especially important due to
423 three aspects. Firstly, most TB cases and deaths are concentrated in LMICs with eight countries comprising of
424 around two-thirds of the burden worldwide⁴¹. Secondly, epidemiological variations among countries influence
425 TB vaccine implementation. Therefore, factors such as TB/HIV prevalence, tuberculosis infections (TBI) rates,
426 BCG vaccine coverage, and multi-drug resistant (MDR)-TB burden must be considered. Thirdly, while BCG
427 revaccination and M72/AS01E vaccine candidates are advanced, they may not be suitable for all contexts and
428 populations.

429
430 Further clinical research is needed to identify which vaccines are likely effective and approvable. This will
431 guide the characteristics to consider in future modelling. Currently, research primarily relies on expert
432 opinions, but it lacks essential acceptability assessments among end users. Although cross-country
433 representation is significant, we need to consider necessary specific target populations within each country. As
434 shown in this review, different countries have varying target populations, each with distinct estimated impacts
435 and coverage levels. It is vital to expand research to include other LMICs, various target populations, and late-
436 stage vaccine candidates. This broader approach will enhance our understanding of vaccine characteristics,
437 leading to better decision-making and equitable distribution.

438 Understanding the TB burden and TB infection rates within various target populations across countries is
439 paramount for optimizing the potential benefits of new and/or repurposed TB vaccines. This foundational
440 knowledge serves as the basis upon which tailored vaccine implementation strategies can be formulated.
441 Crucially, the development of implementation strategies should be guided by feasibility and equity
442 considerations. These strategies should be linked to the TB burden in specific regions, considering contextual
443 factors and health disparities that impact the effective deployment of TB vaccines. The experiences of China,
444 India, and South Africa, which have chosen routine vaccination as a practical implementation strategy,
445 underscore the feasibility of integrating new and repurposed vaccines into existing vaccination programs.
446 Consequently, we recommend future TB vaccine preparedness research to investigate country-specific TB/TBI
447 rates within target populations.

448
449 Further examination of factors such as stigma, accessibility, availability, vaccine hesitancy, and vaccine
450 confidence, along with an exploration of the mechanisms, facilitators, and barriers influencing these aspects,
451 holds pivotal significance. These determinants exert a direct impact on the acceptance, adoption, and uptake
452 of novel or repurposed TB vaccines. Considerations like community beliefs and attitudes, equitable
453 representation, and individual choices regarding vaccination are subsequently essential for informing the
454 landscape of acceptability and feasibility. Regrettably, the existing body of research exhibits a conspicuous gap
455 in knowledge, as no prior studies have delved into these critical topics. Gallagher et al.⁴² and McClure et al.⁴³
456 underscore the significance of addressing hesitancy and rumors, as these factors can detrimentally affect
457 vaccine programs on a broader scale. The absence of research in this domain underscores the urgent necessity
458 for comprehensive investigations aimed at better comprehending the dynamics that shape individuals'
459 attitudes, perceptions, and behaviors towards TB vaccines.

460
461 Furthermore, it is of utmost importance to assess the readiness of healthcare systems in (LMICs for the
462 seamless integration of new and repurposed TB vaccines. Experience from the implementation research of
463 COVID-19 vaccination has highlighted the critical importance of health system readiness⁴⁴. This readiness is
464 essential to mitigate delays and prevent losses in the implementation of TB vaccines and should encompass an
465 evaluation of healthcare infrastructure, capacity, and potential obstacles, enabling the development of well-
466 informed strategies that facilitate successful implementation. See table 12 for an overview of the prioritized
467 gaps for future research to guide new and repurposed TB vaccine implementation.

468 Our study has limitations. Notably, we conducted a scoping review, which is distinct from a comprehensive
469 systematic review. While we employed diverse methods to comprehensively map the existing literature and
470 identify gaps, it is possible that some relevant studies may have been inadvertently omitted. Nevertheless, our
471 primary aim was to present a comprehensive overview of the current state of the field, rather than striving for
472 an exhaustive compilation. Additionally, our scope was exclusively focused on TB vaccine implementation.
473 Over recent years, however, much experience has been gained with implementation of vaccinations for adults
474 and adolescents e.g., COVID-19, Hepatitis B, and HPV. These lessons learned would be very relevant and
475 valuable to the implementation of a new or repurposed TB vaccine in the same age groups. Despite these
476 limitations, it is the first review to comprehensively map the existing literature on the implementation and
477 impacts of new and repurposed TB vaccines. This provides stakeholders with a clear overview of the current
478 body of knowledge, enhancing the understanding of stakeholders regarding the current landscape and aiding
479 them in prioritizing future research in this area.
480

481 Conclusion

482 With several TB vaccine candidates in the pipeline, there is an urgent need for research on the global
483 implementation of effective TB vaccines among adult and adolescent populations, including assessment of
484 economic and epidemiological impacts in LMICs. Country-specific evidence on TB vaccine implementation is
485 also imperative but is currently lacking. Addressing these gaps will be needed to prepare countries for novel
486 TB vaccine implementation, upon approval, to ensure uptake through the design of optimal and equitable
487 vaccine implementation strategies. Future studies should focus on generating evidence on understudied areas
488 such as key factors influencing acceptability and implementation feasibility. Furthermore, geographic and
489 population diversity should be seriously considered when planning further studies to understand TB vaccine
490 implementation strategies.

491 [Author contributions](#)

492 JSB, PTP, DJ and AG conceived the study and wrote the protocol. JSB performed a systematic search and
493 screened and identified studies. PTP validated and verified the search, screening, and identification. JSB and
494 PTP made final decisions regarding study inclusion. JSB and PTP wrote the first draft of this manuscript. RB, DJ,
495 and AG contributed to data analysis and interpretation and manuscript review and revision. ADK AM, and RL
496 reviewed the protocols and revised the manuscript. All authors have read and edited the drafted manuscript.
497 All authors approved the final version of the manuscript.
498

499 [Acknowledgements](#)

500 This review is executed under the SMART4TB project. SMART4TB is made possible by the generous support of
501 the American people through the United States Agency for International Development (USAID) and is
502 implemented under cooperative agreement number 7200AA20CA00005. The consortium is managed by
503 prime recipient, Johns Hopkins University.

Reference

1. Global tuberculosis report 2023. <https://www.who.int/publications-detail-redirect/9789240083851>.
2. Lancione, S., Alvarez, J. V., Alsdurf, H., Pai, M. & Zwerling, A. A. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. *BMJ Glob. Health* **7**, e007462 (2022).
3. Martinez, L. BCG Vaccination and Risk Pulmonary, Extrapulmonary, and All Forms of Tuberculosis Throughout the Life Course. *Unpubl. Results*.
4. BCG vaccines: WHO position paper – February 2018. *Releve Epidemiol. Hebd.* **93**, 73–96 (2018).
5. Tait, D. R. *et al.* Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. *N. Engl. J. Med.* **381**, 2429–2439 (2019).
6. Nemes, E. *et al.* Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. *N. Engl. J. Med.* **379**, 138–149 (2018).
7. Harris, R. C., Sumner, T., Knight, G. M. & White, R. G. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. *Hum. Vaccines Immunother.* **12**, 2813–2832 (2016).
8. Global TB vaccine R&D roadmap. *EDCTP* <https://www.edctp.org/our-work/global-tb-vaccine-rd-roadmap/>.
9. Kochhar, S. *et al.* Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. *Vaccine* **40**, 1681–1690 (2022).
10. Popay, J. *et al.* Guidance on the Conduct of Narrative Synthesis in Systematic Reviews.
11. Atun, R., De Jongh, T., Secci, F., Ohiri, K. & Adeyi, O. Integration of targeted health interventions into health systems: A conceptual framework for analysis. *Health Policy Plan.* **25**, 104–111 (2010).
12. World Health Organization. *Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies*. (World Health Organization, 2010).
13. Arinaminpathy, N., Mukadi, Y. D., Bloom, A., Vincent, C. & Ahmedov, S. Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio. *medRxiv* 2022.10.20.22281311-2022.10.20.22281311 (2022) doi:10.1101/2022.10.20.22281311.
14. Fu, H., Lewnard, J. A., Frost, I., Laxminarayan, R. & Arinaminpathy, N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. *Nat. Commun.* **12**, 424 (2021).

15. Clark, R. A. *et al.* The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study. *Lancet Glob. Health* **11**, e546–e555 (2023).
16. Allison Portnoy *et al.* The potential impact of novel tuberculosis vaccines on health equity and financial protection in low- and middle-income countries. *medRxiv* 2022.10.29.22281678 (2022) doi:10.1101/2022.10.29.22281678.
17. Knight, G. M. *et al.* Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 15520–15525 (2014).
18. Harris, R. C. *et al.* Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. *Lancet Glob. Health* **7**, e209–e218 (2019).
19. Jayawardana, S. *et al.* Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis. *Npj Vaccines* **7**, 1–8 (2022).
20. Harris, R. C., Sumner, T., Knight, G. M., Zhang, H. & White, R. G. Potential impact of tuberculosis vaccines in China, South Africa, and India. *Sci. Transl. Med.* **12**, eaax4607 (2020).
21. Shrestha, S. *et al.* Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. *Am. J. Epidemiol.* **186**, 1362–1369 (2017).
22. Shrestha, S., Chatterjee, S., Rao, K. D. & Dowdy, D. W. Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India. *J. R. Soc. Interface* **13**, 20151016 (2016).
23. Silva, S. *et al.* *The Health and Economic Benefits Possible with Novel Tuberculosis Vaccines – A Modeling Study in India and Indonesia.* (2021). doi:10.21203/rs.3.rs-265017/v1.
24. Weerasuriya, C. K. *et al.* The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. *BMC Med.* **19**, 60 (2021).
25. Dye, C. Making wider use of the world’s most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered. *J. R. Soc. Interface* **10**, 20130365 (2013).
26. Liu, S., Li, Y., Bi, Y. & Huang, Q. Mixed vaccination strategy for the control of tuberculosis: A case study in China. *Math. Biosci. Eng. MBE* **14**, 695–708 (2017).
27. Awad, S. F., Critchley, J. A. & Abu-Raddad, L. J. Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions. *Epidemics* **30**, 100381 (2020).

28. Rebecca A Clark *et al.* New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01_E and BCG-revaccination. *medRxiv* 2023.02.24.23286406 (2023) doi:10.1101/2023.02.24.23286406.
29. Renardy, M. & Kirschner, D. E. Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings. *J. Theor. Biol.* **469**, 1–11 (2019).
30. Portnoy, A. *et al.* The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. *PLOS Med.* **20**, e1004155 (2023).
31. Allison Portnoy *et al.* The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries. *medRxiv* 2022.11.23.22282690 (2022) doi:10.1101/2022.11.23.22282690.
32. Harris, R. C. *et al.* Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. *Nat. Commun.* **13**, 602 (2022).
33. Weerasuriya, C. K. *et al.* Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis. *Vaccines* **9**, 245 (2021).
34. Pelzer, P. T. *et al.* Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines. *PLOS Glob. Public Health* **2**, e0000076 (2022).
35. Hatherill, M. *et al.* BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **62 Suppl 3**, S262-267 (2016).
36. Humiston, S. G. & Rosenthal, S. L. Challenges to vaccinating adolescents: vaccine implementation issues. *Pediatr. Infect. Dis. J.* **24**, S134-140 (2005).
37. Gallagher, K. E., LaMontagne, D. S. & Watson-Jones, D. Status of HPV vaccine introduction and barriers to country uptake. *Vaccine* **36**, 4761–4767 (2018).
38. Tsu, V. D., LaMontagne, D. S., Atuhebwe, P., Bloem, P. N. & Ndiaye, C. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and prospects. *Prev. Med.* **144**, 106335 (2021).
39. Ayenigbara, I. O., Adegboro, J. S., Ayenigbara, G. O., Adeleke, O. R. & Olofintuyi, O. O. The challenges to a successful COVID-19 vaccination programme in Africa. *Germs* **11**, 427–440 (2021).

40. Wang, S. A. *et al.* New vaccine introductions: Assessing the impact and the opportunities for immunization and health systems strengthening. *Vaccine* **31**, B122 (2013).
41. Global Tuberculosis Report 2022. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022>.
42. Gallagher, K. E., LaMontagne, D. S. & Watson-Jones, D. Status of HPV vaccine introduction and barriers to country uptake. *Vaccine* **36**, 4761–4767 (2018).
43. McClure, C. C., Cataldi, J. R. & O’Leary, S. T. Vaccine Hesitancy: Where We Are and Where We Are Going. *Clin. Ther.* **39**, 1550–1562 (2017).
44. Evans, S., Holt, D., Weil-Olivier, C., Finnegan, G. & Usonis, V. Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy. *Vaccine* **40**, 3511–3513 (2022).

Annex A – Search Strings

database	concept	Search string	filters
PubMed	#1 tuberculosis	“Tuberculosis”[MeSH Terms]	
	#2 Tuberculosis vaccination	“Tuberculosis vaccines” [MeSH Terms] OR “tb vaccin*”[Title/Abstract] OR “tuberculosis vaccin*”[Title/Abstract]	
	#3 Vaccine preparedness	“Immunization Programs”[MeSH Terms] OR “Vaccination Refusal”[MeSH Terms] OR “Vaccination Coverage”[MeSH Terms] OR “Vaccination Hesitancy”[MeSH Terms] OR “implement*”[Title/Abstract] OR “strateg*”[Title/Abstract] OR “barrier*”[Title/Abstract] OR “enabler*”[Title/Abstract] OR “factor*”[Title/Abstract] OR “health system*”[Title/Abstract] OR “prepare*”[Title/Abstract] OR “readiness”[Title/Abstract] OR “roll out”[Title/Abstract] OR “impact”[Title/Abstract] OR “effect*”[Title/Abstract] OR “intro*”[Title/Abstract] OR “uptake”[Title/Abstract] OR “accept*”[Title/Abstract] OR “availab*”[Title/Abstract] OR “access*”[Title/Abstract] OR “feasib*”[Title/Abstract] OR “human resources*”[Title/Abstract] OR “capacity*”[Title/Abstract] OR “coordinat*”[Title/Abstract] OR “training*”[Title/Abstract] OR “cost*”[Title/Abstract] OR “financ*”[Title/Abstract] OR “govern*”[Title/Abstract] OR	

		“regulat*”[Title/Abstract] OR “service deliver*”[Title/Abstract] OR “scale up*”[Title/Abstract] OR “scalib*”[Title/Abstract] OR “hesitan*”[Title/Abstract] OR “facilitat*” [Title/Abstract]	
	Combined with exclusion	#1 AND #2 AND #3 AND “Humans” [Mesh] NOT “Clinical Study” [Publication type] NOT “Infant” [Mesh] NOT “Child, Preschool” [Mesh] NOT “Immunity” [Mesh]	Year: 2013-2023
Medrxiv	Tuberculosis vaccin	for term “tuberculosis vaccin” and abstract or title “adolescent adult” (match any words) and posted between “1 st of Jan 2013 and 30 th of Apr, 2023”	Year: 2013-2023
Plos Global public health	Vaccine and tuberculosis	((abstract:vaccin) AND abstract:tuberculosis)	Year: 2013-2023

Annex B – Supplementary tables

Table 2. number of included studies per country, vaccine readiness focus, vaccine candidate and profile, and vaccine endpoint.

	LMIC’s/high burden countries	China	India	South Africa	Cambodia	Indonesia
Nr. studies	7	6	9	7	1	1
Vaccine readiness focus						
Epidemiological	4 ^{13-15,17}	4 ^{18,20,24,26}	6 ^{20,22-24,27,28}	4 ^{19-21,25;}	1 ²⁹	1 ²³
Costing, cost-effectiveness, economic	4 ^{16,17,30,31}	2 ^{24,33;}	5 ^{23,24,28,32,33}	3 ^{19,25,32}	-	1 ²³
Acceptability	8	1 ³⁴	1 ³⁴	1 ³⁴	-	-
Implementation feasibility	-	1 ³⁴	2 ^{22,34}	4 ^{19,21,34,35}	-	-
Vaccine candidate or profile						
Generic	6 ^{13,15-17,30,31}	3 ^{18,24,26}	4 ^{22,24,27,28}	2 ^{21,35}	1 ²⁹	-
M72/AS01	1 ¹⁴	3 ^{20,24,34}	6 ^{20,23,28,32-34}	4 ^{19,20,32,34}	-	1 ²³
BCG revaccination	-	2 ^{20,34}	3 ^{20,28,34}	4 ^{20,25,34,35,}	-	-
Endpoint generic vaccines						
PoD	6 ^{13,15-17,30,31}	2 ^{18,24}	3 ^{22,24,27}	2 ^{21,35}	1 ²⁹	-
Pol	-	2 ^{24,26}	3 ^{24,27,28}	1 ³⁵	1 ²⁹	-
PoR	-	-	-	-	-	-

Table 3. Overview characteristics included articles.

First author, year,	Type of literature	Type of study	country	Type of vaccine	Target population	Implementation strategy	Health impact	Economic impact	Acceptability	Feasibility
Pelzer, 2021	white	Qualitative	China, India, South Africa	BCG revax & MS72 /AS01E	various; adolescents, general population, elderly,	mass campaigns, school program, routine immunization program,			x	x

⁸ No studies identified.

					healthcare workers, high risk contacts, socially vulnerable groups, biological high-risk groups,	workplace, health visitations				
Harris, 2019	white	Modelling	China	Generic vaccine (POD)	elderly & adolescents	yearly routine vaccination; catch up campaigns for specific age groups	x			
Hatherill, 2016	white	Supplement	South Africa	Generic vaccine (POD/POI) and BCG revax	Healthcare workers	not specific				x
Harris, 2022	white	Modelling	India, South Africa	MS72/AS01E	adolescents	routine vaccination		x		
Shrestha, 2017	white	Modelling	South Africa	Generic vaccine (POD)	miners and mine-labor-sending community	not specific	x			x
Dye, 2013	white	Modelling	South Africa	BCG revax	adolescents (teenagers)	not specific	x	x		
Arinaminpathy, 2022	Pre-print	Modelling	Countries USAID TB portfolio	Generic vaccine (POD)	general population	not specific	x			
Liu, 2017	white	Modelling	China	Generic vaccine (POI)	general population	mixed vaccination: constant vaccination among new and repurposed pulse vaccination strategy among all other age groups through government agencies and companies	x			
Fu, 2021	white	Modelling	high RR-TB incidence countries	MS72/AS01E	adults, adolescents	routine vaccination and catch-up campaigns amongst those over 15-years old	x			
Clark, 2023a	preprint	modelling	India	BCG revax, MS72 /AS01E, generic vaccine (POI)	general adults/adolescents	combination of routine vaccination, mass campaigns and a repeat campaign	x	x		
Portnoy, 2023	white	modelling	105 LMIC	Generic vaccine (POD)	general adults/adolescents	routine vaccination and a onetime vaccination campaign		x		
Weerasuriya, 2021a	white	modelling	China, India	Generic vaccine (POD & POI)	early adolescents	annual routine vaccination, co-delivered with HPV vaccine; mass campaigns	x	x		
Clark, 2023b	white	modelling	105LMICs	Generic vaccine (POD)	adults/adolescents	routine vaccination; mass campaign	x			
Portnoy, 2022a	preprint	modelling	105LMICs	Generic vaccine (POD)	general adults/adolescents	an initial mass vaccination campaign followed by routine vaccinations		x		

Portnoy, 2022b	preprint	modelling	105LMICs	Generic vaccine (POD)	general adults/adolescents	Routine vaccination plus a one-time vaccination campaign		x		
Harris, 2020	white	modelling	China, India, South Africa	BCG revax & MS72 /AS01E	general adults and adolescents	routine vaccination and mass campaigns	x			
Weerasuriya, 2021b	white	modelling	China, India	MS72/AS01E	early adolescents	mass vaccination		x		
Awad, 2020	white	modelling	India	Generic vaccine (POD & POI)	people with diabetes	not specific	x			
Renardy, 2019	white	modelling	Cambodia	Generic vaccine (POD & POI)	general adults/adolescents	not specific	x			
Knight, 2014	white	modelling	LMIC's	Generic vaccine (POD)	general adults/adolescents	school and mass vaccination programs	x	x		
Shrestha, 2016	white	modelling	India	Generic vaccine (POD)	general adults/adolescents	yearly routine vaccination and 10y-periodic revaccination	x			x
Silva, 2021	preprint	modelling	India, Indonesia	MS72/AS01E	general adults	not specific	x	x		
Jayawardana, 2022	white	qualitative +modelling study	South Africa	MS72/AS01E	adults/adolescents + PLHIV adults	adults/adolescents : 1. mass + routine and 2. 2x mass. PLHIV adults: 1. mass & routine, 2. 2xmassadults	x	x		x

Table 6. Study characteristics and main measurement outcomes from epidemiological impact studies by country.

	LMICs	India	South Africa	China	Indonesia	Cambodia
Nr. studies	4	6	4	4	1	1
Vaccine type						
BCG	0	2	2	1	0	0
M72/AS01E	1	3	2	1	1	0
Generic vaccine	3	4	1	3	0	1
Endpoint generic vaccines						
POI	0	3		2	0	1
POD	3	3	1	2	0	1
POR	0	0	0	0	0	0
Target population						
Adults and adolescents	4	5	2	2	1	1
Other	0	1 ⁹	3 ¹⁰	2 ¹¹	0	0
Measurement of outcomes						
Incidence	5 ¹²	5 ⁹	4	4 ⁹	0	1
Mortality	3	4 ⁹	2	3 ⁹	1	0

Table 7. Study characteristics and main measurement outcomes from studies modelling costing, cost-effectiveness, economic impacts by country.

	LMIC's	India	South Africa	China	Indonesia
--	--------	-------	--------------	-------	-----------

⁹ People with diabetes mellitus

¹⁰ Miners and labour sending community, PLHIV, adolescents only.

¹¹ General population, adolescents +elderly

¹² Of which 1 focuses on RR-TB

Nr. Studies	4	5	3	2	1
Vaccine type					
BCG	0	1	1	0	0
M72/AS01E	0	4	2	1	1
Generic vaccine	4	2	0	1	0
Endpoint generic vaccines					
POI	0	2	0	1	0
POD	4	5=1	0	1	0
POR	0	0	0	0	0
Target population					
Adults and adolescents	4	4	1	2	1
Other	0	1 ¹³	2 ¹⁴	0	0
Measurement outcomes					
GDP gains	1	0	0	0	0
Cost-effectiveness	2	2	2	1	0
TB vaccination program cost	0	3	0	1	0
Threshold willingness to pay	0	1	0	1	0
Averted cost per income quintile	1	0	0	0	0
Full-income gains	0	1	0	0	1

Table 9. Characteristics of studies evaluating facets related to implementation feasibility by country.

	India	South Africa	China
Nr studies feasibility	2	4	1
Vaccine type			
BCG	1	2	1
M72/AS01E	1	2	1
Generic vaccine	1	2	0
Endpoint generic vaccines			
POI	0	1	0
POD	1	2	0
POR	0	0	0
Target population			
Adolescents	1	1	1
Adults	1	1	1
Elderly	1	0	1
Socially vulnerable groups	1	1	1
PLHIV	1	1	1
Immunocompromised groups	1	1	1
Healthcare worker	1	2	1

¹³ Adolescents only

¹⁴ Adolescents only, PLHIV adults

Other	2 ¹⁵	1 ¹⁶	1 ¹⁷
Implementation strategies	2	4	1
Health system readiness	1	1	1

Table 12. Prioritized gaps for future research to guide new and repurposed TB vaccine implementation.

	Geographical	Vaccine related	Data/ Tools	Other
Overall	Country specific evidence	<ul style="list-style-type: none"> Other pipeline candidates PoI, PoR vaccines 		<ul style="list-style-type: none"> After 2050, i.e., long-term impact Various target populations
Epidemiological impact	<ul style="list-style-type: none"> Global, country specific evidence 	<ul style="list-style-type: none"> Other pipeline candidates PoI vaccines, Validated VE Impact without prior BCG 	<ul style="list-style-type: none"> Country validated estimates. Target population estimates 	<ul style="list-style-type: none"> Combination with other TB interventions Country specific target populations
Economic impact	<ul style="list-style-type: none"> Global, country-specific context 	<ul style="list-style-type: none"> PoD, PoI, PoR vaccines 	<ul style="list-style-type: none"> thresholds for cost-effectiveness 	<ul style="list-style-type: none"> Coverage Timing of a program, Combination with other TB intervention country specific target populations
Implementation feasibility	<ul style="list-style-type: none"> Global, country specific evidence 	<ul style="list-style-type: none"> PoD, PoI, PoR vaccines 	<ul style="list-style-type: none"> Implementation strategies Health system readiness assessment Acceptability Health equity 	<ul style="list-style-type: none"> Geographic analysis of accessibility to vaccine locations
Acceptability	<ul style="list-style-type: none"> Global, country specific evidence 	<ul style="list-style-type: none"> PoD, PoI, PoR vaccines 	<ul style="list-style-type: none"> Attitudes, beliefs, perceptions, preferences, decision-making metrics 	<ul style="list-style-type: none"> Acceptability among target populations Preferences of target populations, including in comparison to other TB interventions
Implementation strategies	<ul style="list-style-type: none"> Global, country specific evidence 	<ul style="list-style-type: none"> PoD, PoI, PoR vaccines 	<ul style="list-style-type: none"> Implementation strategies 	<ul style="list-style-type: none"> Country specific target populations

¹⁵ High-risk contact, high resource areas and occupational groups, spatially targeted vaccines in geographic hotspots

¹⁶ Mining population

¹⁷ High-risk contact, high resource areas and occupational groups

Health system readiness	<ul style="list-style-type: none">• Global, country specific	<ul style="list-style-type: none">• PoD, PoI, PoR vaccines	<ul style="list-style-type: none">• Validated assessment tool• Country validated essential indicators	<ul style="list-style-type: none">• Country specific target populations• Geographic analysis of catchment areas of expected vaccine locations
-------------------------	--	--	--	--